Ionis Pharmaceuticals (IONS) Total Current Liabilities (2009 - 2026)
Ionis Pharmaceuticals (IONS) posted quarterly Total Current Liabilities of $315.6 million for Q2 2026, down 64.82% year-over-year from $897.2 million in Q2 2025, and down 55.95% quarter-over-quarter from $716.6 million in Q1 2026.
Ionis Pharmaceuticals (IONS) Total Current Liabilities (2009 - 2026) Analysis & Trends
Ionis Pharmaceuticals' Total Current Liabilities history runs 18 years deep, the most recent figure standing at $315.6 million for Q2 2026.
- In Q2 2026, Total Current Liabilities fell 64.82% year-over-year to $315.6 million; the TTM figure through Jun 2026 stood at $315.6 million (down 64.82% YoY), while the FY2025 annual figure was $781.6 million, up 152.67% from the prior year.
- Total Current Liabilities for Q2 2026 stood at $315.6 million, down from $716.6 million in the prior quarter.
- The five-year high for Total Current Liabilities was $903.5 million in Q3 2025, with the low at $228.4 million in Q1 2022.
- The 5-year median for Total Current Liabilities is $310.4 million (2022), against an average of $422.4 million.
- The sharpest annual moves came in 2025 and 2026: Total Current Liabilities soared 196.64% in 2025, then slumped 64.82% in 2026.
- Ionis Pharmaceuticals' Total Current Liabilities stood at $311.6 million in 2022, then surged by 43.82% to $448.1 million in 2023, then tumbled by 30.97% to $309.3 million in 2024, then jumped by 152.67% to $781.6 million in 2025, then sank by 59.61% to $315.6 million in 2026.
- Business Quant data shows IONS's Total Current Liabilities at $315.6 million in Q2 2026, $716.6 million in Q1 2026, and $781.6 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Ionis Pharmaceuticals | 9.48 Bn | 7.43 Bn | 265.21 Mn | 315.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 315.64 Mn |
| Mar 31, 2026 | 716.59 Mn |
| Dec 31, 2025 | 781.57 Mn |
| Sep 30, 2025 | 903.46 Mn |
| Jun 30, 2025 | 897.24 Mn |
| Mar 31, 2025 | 250.29 Mn |
| Dec 31, 2024 | 309.32 Mn |
| Sep 30, 2024 | 304.57 Mn |
| Jun 30, 2024 | 306.16 Mn |
| Mar 31, 2024 | 327.65 Mn |
| Dec 31, 2023 | 448.09 Mn |
| Sep 30, 2023 | 404.21 Mn |
| Jun 30, 2023 | 287.98 Mn |
| Mar 31, 2023 | 259.22 Mn |
| Dec 31, 2022 | 311.56 Mn |
| Sep 30, 2022 | 283.45 Mn |
| Jun 30, 2022 | 267.81 Mn |
| Mar 31, 2022 | 228.45 Mn |
| Dec 31, 2021 | 240.55 Mn |
| Sep 30, 2021 | 279.78 Mn |